Benchmark Research Announces New Shreveport Site
Benchmark Research has announced a new site located in Shreveport, Louisiana will bring the company to 9 sites total across the states of Texas, California, and Louisiana. This clinic will be Benchmark’s first to focus on In-patient and out-patient psychiatric studies as well as groundbreaking studies with Cannabis and Psychedelics such as LSD, Psilocybin, Ketamine, MDMA, and others.
Benchmark Shreveport (SHV) will be spearheaded by Brian Wooten, the prior owner of the clinic. Brian is a CCRC with a master’s degree in clinical psychology. In the past 27 years throughout his career, he has held various positions in psychiatric medicine management including 25 years in various roles in psychiatric clinical research from CRC to site owner.
Read more about the new clinic here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
First Patient Dosed in Phase III Trial of Enhertu as First-Line Treatment for Endometrial Cancer
June 10th 2025In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 study for the treatment of patients with HER2-expressing, mismatch repair proficient primary advanced or recurrent endometrial cancer.
